Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...
Robert Kennedy Jr. will keep his share of any windfall from litigation against Merck (MRK) even if he becomes Donald Trump’s top U.S. health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback